A Randomized, Double-Blind, Placebo-Controlled Trial of Oral Matricaria recutita (Chamomile) Extract Therapy for Generalized Anxiety Disorder
- 1 August 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Clinical Psychopharmacology
- Vol. 29 (4), 378-382
- https://doi.org/10.1097/jcp.0b013e3181ac935c
Abstract
Objective: We conducted a randomized, double-blind, placebo-controlled efficacy and tolerability trial of Matricaria recutita (chamomile) extract therapy in patients with mild to moderate generalized anxiety disorder (GAD). We hypothesized that chamomile would be superior to placebo in reducing GAD symptoms with a comparable tolerability profile. Materials and Methods: Sixty-one outpatients with mild to moderate GAD were enrolled, and 57 were randomized to either double-blind chamomile extract (n = 28) or placebo therapy (n = 29) for 8 weeks. The study was powered to detect a statistically significant and clinically meaningful group difference in change over time in total Hamilton Anxiety Rating (HAM-A) scores. Secondary outcomes included change in the Beck Anxiety Inventory, Psychological Well Being, and Clinical Global Impression Severity scores and the proportion of patients with 50% reduction or more in baseline HAM-A score. Results: We observed a significantly greater reduction in mean total HAM-A score during chamomile versus placebo therapy (P = 0.047). Although the study was not powered to identify small to moderate differences in secondary outcomes, we observed a positive change in all secondary outcomes in the same direction as the primary outcome measure. One patient in each treatment group discontinued therapy for adverse events. The proportion of patients experiencing 0, 1, 2, or 3 adverse events or more was not significantly different between groups (P = 0.417). Conclusions: This is the first controlled clinical trial of chamomile extract for GAD. The results suggest that chamomile may have modest anxiolytic activity in patients with mild to moderate GAD. Future studies are needed to replicate these observations.This publication has 25 references indexed in Scilit:
- Stigma and the Acceptability of Depression Treatments Among African Americans and WhitesJournal of General Internal Medicine, 2007
- Use of complementary and alternative medicine and prayer among a national sample of cancer survivors compared to other populations without cancerComplementary Therapies in Medicine, 2007
- Access To Conventional Medical Care And The Use Of Complementary And Alternative MedicineHealth Affairs, 2005
- Apigenin modulates GABAergic and glutamatergic transmission in cultured cortical neuronsEuropean Journal of Pharmacology, 2004
- Generalized anxiety disorder: prevalence, burden, and cost to societyDepression and Anxiety, 2002
- Evidence-based pharmacotherapy of Generalized Anxiety DisorderInternational Journal of Neuropsychopharmacology, 1999
- Involvement of monoamine oxidase and noradrenaline uptake in the positive chronotropic effects of apigenin in rat atriaEuropean Journal of Pharmacology, 1996
- Effect of Inhalation of Chamomile Oil Vapour on Plasma ACTH Level in Ovariectomized-Rat Under Restriction Stress.Biological & Pharmaceutical Bulletin, 1996
- An inventory for measuring clinical anxiety: Psychometric properties.Journal of Consulting and Clinical Psychology, 1988
- THE ASSESSMENT OF ANXIETY STATES BY RATINGPsychology and Psychotherapy: Theory, Research and Practice, 1959